Global Fund - Global Drug Facility invitation to manufacturers of Tuberculosis medicines to submit and EoI

The purpose of this EoI is to invite submissions of first, second and third line anit-tuberculosis product dossiers for review by the Expert Review Panel for which there are less than three products of the same formulations that are WHO-Prequalified of SRA-approved or ERP-reviewed, available  in the global market.

The Global Fund and the Global Drug Facility (GDF) are using the same ERP process (in terms of products, questionnaire dossier, process mechanism hosted by QSM as described at http://www.theglobalfund.org/en/procurement/pharmaceutical/ under "A, B and ERP- reviewed products"). The synchronization of the dossier review process for non-WHO prequalified or non-SRA authorized TB products has been accepted by the WHO, GDF and the Global Fund. This should minimize duplication of work for manufacturers and ERP members.